cefiderocol sulfate tosylate - Profile

What are the generic sources for cefiderocol sulfate tosylate and what is the scope of freedom to operate?

Cefiderocol sulfate tosylate is the generic ingredient in one branded drug marketed by Shionogi Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cefiderocol sulfate tosylate has eighty-six patent family members in thirty-eight countries.

Summary for cefiderocol sulfate tosylate

International Patents:	86
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cefiderocol sulfate tosylate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for cefiderocol sulfate tosylate

Constraining patent/regulatory exclusivity:

10,004,750

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for cefiderocol sulfate tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes	9,238,657		Y	Y
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes	10,004,750		Y	Y
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes	9,949,982		Y
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes

International Patents for cefiderocol sulfate tosylate

Country	Patent Number	Title	Estimated Expiration
Ukraine	105190	ЦЕФАЛОСПОРИНЫ, КОТОРЫЕ СОДЕРЖАТ КАТЕХОЛЬНУЮ ГРУППУ;ЦЕФАЛОСПОРИНИ, ЯКІ МІСТЯТЬ КАТЕХОЛЬНУ ГРУПУ (CEPHALOSPORINS HAVING CATECHOL GROUP)
Eurasian Patent Organization	201790522
San Marino	T201600397	CEFALOSPORINA AVENTE UN GRUPPO CATECOLO
China	102203100
Japan	2014065732
European Patent Office	3189841	PRÉPARATION PHARMACEUTIQUE COMPRENANT UNE CÉPHALOSPORINE AYANT DES GROUPES CATÉCHOL (PHARMACEUTICAL PREPARATION COMPRISING CEPHALOSPORIN HAVING CATECHOL GROUPS)

Supplementary Protection Certificates for cefiderocol sulfate tosylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2960244	2090041-1	Sweden		PRODUCT NAME: CEFIDEROKOL; REG. NO/DATE: EU/1/20/1434 20200424
2960244	2020035	Norway		PRODUCT NAME: CEFIDEROKOL, EVENTUELT PA FORMEN AV ET FARMASOEYTISK AKSEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200508
2960244	C202030051	Spain		PRODUCT NAME: CEFIDEROCOL, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE.; NATIONAL AUTHORISATION NUMBER: EU/1/20/1434; DATE OF AUTHORISATION: 20200423; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1434; DATE OF FIRST AUTHORISATION IN EEA: 20200423
2960244	2020/044	Ireland		PRODUCT NAME: CEFIDEROCOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT REGISTRATION NO/DATE: EU/1/20/1434 20200424; FIRST REGISTRATION NO/DATE: EU/1/20/1434 20200424
2960244	PA2020530	Lithuania		PRODUCT NAME: CEFIDEROKOLAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1434 20200423
2960244	122020000060	Germany		PRODUCT NAME: CEFIDEROCOL; REGISTRATION NO/DATE: EU/1/20/1434 20200423

Cefiderocol Sulfate Tosylate: Market Dynamics, Investment Scenario, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Cefiderocol sulfate tosylate is a novel siderophore cephalosporin antibiotic approved by the US FDA in 2019 for complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP). Its unique mechanism targeting multidrug-resistant gram-negative bacteria positions it as a promising asset in the escalating fight against antimicrobial resistance (AMR). This report assesses the current and projected market landscape, investment potential, and financial trajectory of cefiderocol sulfate tosylate, focusing on key determinants such as market demand, competitive dynamics, regulatory pathways, and pricing strategies.

---

What Is the Current Market Size and Potential Demand?

Global Antimicrobial Resistance Market Overview

Year	Market Size (USD Billion)	CAGR (2019-2026)	Key Drivers
2022	$11.1	6.4%	Rising AMR, limited effective antibiotics
2026	$16.9	6.4%	Increased prevalence of multidrug-resistant infections

Sources: [1], [2]

Cefiderocol-Specific Market

• Indications: cUTIs, HABP, ventilator-associated pneumonia (VAP)
• Target Patient Population Estimates (2022):
  • US: ~300,000 cases annually
  • Europe: ~250,000 cases annually
  • Asia-Pacific: Rapidly growing prevalence due to increased nosocomial infections

Market Penetration Estimates

• Early Adoption: Primarily in hospitals treating resistant infections
• Projected Penetration (2025-2030):
  • US & Europe: 45–60% of treated cases
  • Asia-Pacific: Emerging, 20–30% due to infrastructure and awareness growth

---

Market Dynamics Influencing Cefiderocol's Trajectory

1. Competitive Landscape

Competitors	Mechanism	Approvals & Status	Market Share (Estimated)
Meropenem/vaborbactam	Beta-lactamase inhibitor combo	Approved in US, EU	~15%
Cefepime/zidebactam	Beta-lactam/zidebactam combo	Under clinical development	N/A
Plazomicin	Aminoglycoside	Approved in US	~10%
Other new antibiotics (e.g., Meropenem-vaborbactam, Imipenem-relebactam)	Combination therapies	Approved	Varies, dominant in resistant infections

Unique Selling Proposition of Cefiderocol: Siderophore-mimetic mechanism offers activity against multi-resistant gram-negative bacteria, including carbapenem-resistant strains.

2. Regulatory and Reimbursement Policies

• FDA: Approved via Priority Review, Long-term safety data pending
• EMA & Other Markets: Pending approval, with some countries considering accelerated pathways
• Pricing & Reimbursement: US List Price (~$10,000–$15,000 per course); reimbursement varies

3. Resistance Development & Prescribing Behavior

• Resistance Risks: Potential overuse may lead to resistance, requiring stewardship
• Prescriber Acceptance: Limited early; growth tied to clinical evidence, guidelines updates

4. Pricing Strategies and Market Access

Strategy	Impact	Status
Premium pricing	Recoup R&D, maximize margins	Expected, contingent on differentiation
Value-based pricing	Based on clinical outcome & resistance impact	Under discussion, especially in HICs
Volume-based discounting	Ensures broader access	Likely in emerging markets

---

Financial Trajectory Forecast (2023–2030)

Revenue Projections

Year	Estimated Sales (USD Million)	Key Assumptions
2023	$150	Launch Year, limited adoption
2024	$500	Growing acceptance in US, Europe
2025	$1,200	Broader geographic access, uptake in Asia
2026	$2,000	Expanded indications, competition stabilization
2027+	$2,500–3,500	Upon market saturation and potential new indications

Source: [3], projections based on historical launches, pricing, and adoption rates

Profitability and Investment Returns

• R&D Investment: $150–200 million (initial development + clinical trials)
• Manufacturing & Supply Chain Costs: Estimated at 20–25% of sales
• Break-even Point: Expected in 2026–2027 if market penetration targets are met

Investment Drivers

Factor	Impact
Rising AMR & unmet medical needs	High; favors rapid adoption
Clinical efficacy & safety data	Critical; influences prescriber confidence
Regulatory approvals in key markets	Enhances revenue streams
Pricing & reimbursement policies	Significant; determine market access and margins

---

Comparison with Similar Antibiotics

Attribute	Cefiderocol	Meropenem/Vaborbactam	Imipenem/Relebactam
Approval (US)	2019	2018	2019
Spectrum of Activity	Multi-resistant gram-negative bacteria	Carbapenem-resistant Enterobacteriaceae	Gram-negative bacteria, limited resistance
Mechanism	Siderophore-mediated uptake	Beta-lactamase inhibition	Beta-lactamase inhibition
Pricing (per course USD)	$10,000–$15,000	~$5,000	~$4,500
Market Penetration (projected 2025)	30–40% in resistant infections	40–50%	35–45%

---

Regulatory and Policy Considerations

Region/Agency	Status	Impact on Marketable Potential
US FDA	Approved	Favorable for initial market entry
EMA	Pending	Additional market access in EU
China NMPA	Under review	Substantial growth potential in APAC
Global AMR Policies	Support antimicrobial innovation	Facilitates funding and incentive mechanisms

---

Questions and Challenges

• How will emerging resistance affect cefiderocol's long-term efficacy?
• Can pricing strategies balance profitability with global access?
• Will clinical data supporting expanded indications materialize swiftly?
• How will competitive pressure from pipeline candidates impact market share?
• What role do antimicrobial stewardship programs play in adoption policies?

---

Key Takeaways

Aspect	Insights
Market Potential	Substantial, especially in resistant bacterial infections; projections suggest reaching $2–3.5 billion by 2030.
Investment Attractiveness	High, given global AMR trends, unique mechanism, and early approval in critical markets; requires strategic management of resistance and pricing risks.
Competitive Edge	Siderophore mechanism confers activity against difficult-to-treat pathogens, providing differentiation.
Regulatory & Price Dynamics	Success depends on expanding approvals, establishing reimbursement, and demonstrating value over existing therapies.
Long-term Outlook	Favorable if resistance management is prioritized and clinical developments expand indications.

---

Conclusion

Cefiderocol sulfate tosylate stands at a pivotal intersection of antimicrobial innovation and market demand driven by the rising tide of multidrug-resistant gram-negative bacteria. Its financial trajectory will hinge on successful market penetration, prudent stewardship, competitive pricing, and rapid expansion through regulatory approvals. Stakeholders should closely monitor resistance patterns, clinical data, and policy shifts to optimize investment outcomes and maximize societal benefits.

---

FAQs

1. What are the primary drivers for cefiderocol’s market growth?

The main drivers include growing prevalence of multidrug-resistant gram-negative infections, limited current treatment options, and regulatory approvals in key markets like the US and EU. Its unique mechanism targeting resistant bacteria provides a competitive edge.

2. How does cefiderocol compare financially with other last-line antibiotics?

Cefiderocol’s higher per-course cost (~$10,000–$15,000) reflects its novel mechanism and targeting resistant strains, whereas older antibiotics or combination therapies typically cost less (~$4,500–$5,000). However, its superior efficacy against resistant pathogens justifies premium pricing in suitable cases.

3. What are the key regulatory considerations for cefiderocol’s global expansion?

Regulatory pathways vary by region. The US FDA approved it in 2019 via priority review; EMA’s approval is pending. Asia-Pacific markets are evaluating expedited approval pathways amid the urgent need for effective antibiotics. Clear regulatory strategies are essential for market access.

4. How might antimicrobial stewardship impact cefiderocol’s sales?

Stewardship programs aimed at antimicrobial resistance may restrict cefiderocol’s use to resistant infections, potentially limiting immediate volume but supporting higher pricing and preserving efficacy, thus extending its market lifespan.

5. What are the main risks associated with investing in cefiderocol?

Potential risks include development of resistance, delayed or denied regulatory approvals in key markets, pricing and reimbursement challenges, and competition from pipeline agents or alternative therapies. Strategic risk mitigation includes diversified market strategies and ongoing clinical research.

---

References

[1] MarketsandMarkets. "Antimicrobial Resistance Market by Pathogen, Drug Class, and Region," 2022.
[2] Grand View Research. "Global Antibiotics Market Size & Share," 2022.
[3] EvaluatePharma. "Industry Forecast," 2023.